[go: up one dir, main page]

MX2009001642A - Metodos para el tratamiento de leucemia de mieloide aguda. - Google Patents

Metodos para el tratamiento de leucemia de mieloide aguda.

Info

Publication number
MX2009001642A
MX2009001642A MX2009001642A MX2009001642A MX2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A
Authority
MX
Mexico
Prior art keywords
cancer disease
disease modifying
antibodies
treatment
modifying antibodies
Prior art date
Application number
MX2009001642A
Other languages
English (en)
Inventor
David S F Young
Daniel S Pereira
John E Dick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009001642A publication Critical patent/MX2009001642A/es

Links

Classifications

    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a la clasificación, diagnóstico y tratamiento de enfermedades cancerosas (tanto de tumores primarios como de metástasis tumorales), en particular a la mediación de la citotoxicidad de las células tumorales; y más particularmente, al uso de anticuerpos monoclonales aislados, fragmentos de enlace de antígeno de los mismos, y/o anticuerpos modificadores de enfermedades cancerosas (CDMAB), opcionalmente en combinación con uno o más anticuerpos modificadores de enfermedades cancerosas, agentes quimioterapéuticos, y conjugados de los mismos, como un medio para iniciar una respuesta citotóxica a las malignidades hematológicas humanas. La invención se refiere además a ensayos de enlace que utilizan los anticuerpos monoclonales aislados, los fragmentos de enlace de antígeno de los mismos, y/o los anticuerpos modificadores de enfermedades cancerosas de la presente invención. Los anticuerpos modificadores de enfermedades cancerosas se pueden conjugar con toxinas, enzimas, compuestos radioactivos, citoquinas, interferones, fracciones objetivo o reporteras, y células hematogenosas.
MX2009001642A 2008-12-23 2009-02-12 Metodos para el tratamiento de leucemia de mieloide aguda. MX2009001642A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/342,986 US20100158801A1 (en) 2008-12-23 2008-12-23 Methods for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2009001642A true MX2009001642A (es) 2010-06-22

Family

ID=42266423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001642A MX2009001642A (es) 2008-12-23 2009-02-12 Metodos para el tratamiento de leucemia de mieloide aguda.

Country Status (5)

Country Link
US (1) US20100158801A1 (es)
AU (1) AU2009200498A1 (es)
BR (1) BRPI0901452A2 (es)
CA (1) CA2653163A1 (es)
MX (1) MX2009001642A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891299A1 (ru) 2016-01-08 2019-01-31 Аимм Терапьютикс Б.В. Терапевтические антитела к cd9

Also Published As

Publication number Publication date
AU2009200498A1 (en) 2010-07-08
CA2653163A1 (en) 2010-06-23
US20100158801A1 (en) 2010-06-24
BRPI0901452A2 (pt) 2010-09-14

Similar Documents

Publication Publication Date Title
ATE500844T1 (de) Detektion der mcsp-oberflächenexpression einer zelle
AR077998A1 (es) Proteinas terapeuticas de union a dll4
UY30655A1 (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cancer
ECSP109970A (es) Mediacion de citotoxicidad de celulas que evidencian
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
MXPA05011755A (es) Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.
MX2013011363A (es) Anticuerpos para peptidos citosolicos.
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
ECSP099341A (es) Nuevos anticuerpos antiproliferativos
BR112017018778A2 (pt) conjugados anticorpo-fármaco à base de criptoficina com ligantes autodegradantes inovadores
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
UY31258A1 (es) Anticuerpos y fragmentos de anticuerpos ant ephb4
MX2023014282A (es) Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33).
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
PH12022551098A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
UY29029A1 (es) Uso de tinturas de cianina para el diagnóstico de enfermedades asociadas con angiogénesis
CO6630177A2 (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
MX2009001642A (es) Metodos para el tratamiento de leucemia de mieloide aguda.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal